
| Therapeutic Area | MeSH | 
|---|---|
| mental disorders | D001523 | 
| Tradename | Company | Number | Date | Products | 
|---|---|---|---|---|
| ABILIFY ASIMTUFII | Otsuka | N-217006 RX | 2023-04-27 | 2 products, RLD, RS | 
| ABILIFY | Otsuka | N-021436 RX | 2002-11-15 | 6 products, RLD | 
| ABILIFY MAINTENA KIT | Otsuka | N-202971 RX | 2013-02-28 | 4 products, RLD, RS | 
| OPIPZA | Xiamen LP Pharmaceutical | N-216655 RX | 2024-07-22 | 3 products, RLD, RS | 
| Brand Name | Status | Last Update | 
|---|---|---|
| abilify | New Drug Application | 2025-01-29 | 
| abilify abilify | New Drug Application | 2013-08-13 | 
| abilify abilify discmelt | 2008-08-28 | |
| abilify asimtufii | New Drug Application | 2025-04-04 | 
| abilify maintena | New Drug Application | 2025-04-15 | 
| abilify maintena kit | New Drug Application | 2013-04-02 | 
| abilify mycite | New Drug Application | 2025-01-31 | 
| aripiprazole | ANDA | 2025-10-01 | 
| aripiprazole oral solution | ANDA | 2016-08-31 | 
| aristada | New Drug Application | 2025-01-28 | 
| Indication | Ontology | MeSH | ICD-10 | 
|---|---|---|---|
| schizophrenia | EFO_0000692 | D012559 | F20 | 
| schizophrenia spectrum and other psychotic disorders | — | D019967 | — | 
| Patent | Expires | Flag | FDA Information | 
|---|---|---|---|
| Aripiprazole, Abilify Maintena Kit, Otsuka Pharm Co Ltd | |||
| 11648347 | 2034-04-06 | DP | |
| 10525057 | 2034-03-08 | U-543, U-1632, U-2723 | |
| 10980803 | 2033-09-24 | U-543, U-1632 | |
| 11154553 | 2033-09-24 | U-814, U-1632, U-3245 | |
| 11344547 | 2033-09-24 | U-814, U-1632, U-3245 | |
| 11400087 | 2033-09-24 | U-814, U-1632, U-3245 | |
| 7807680 | 2024-10-19 | DP | |
| 8030313 | 2024-10-19 | U-543, U-1632 | |
| 8722679 | 2024-10-19 | DP | |
| Aripiprazole, Abilify Mycite Kit, Otsuka | |||
| 9268909 | 2033-10-15 | DP | U-2168 | 
| 10517507 | 2032-06-13 | DP | |
| 9320455 | 2031-12-15 | DP | |
| 11229378 | 2031-07-11 | DP | |
| 8547248 | 2030-12-18 | DP | U-2167 | 
| 8258962 | 2030-11-25 | DP | |
| 8961412 | 2030-11-17 | DP | |
| 9941931 | 2030-11-04 | DP | |
| 11464423 | 2030-09-15 | DP | |
| 8114021 | 2030-06-21 | DP | |
| 8545402 | 2030-04-27 | DP | |
| 8847766 | 2030-03-29 | DP | U-2167 | 
| 9149577 | 2029-12-15 | DP | |
| 8718193 | 2029-12-05 | DP | |
| 9433371 | 2029-09-15 | DP | |
| 8945005 | 2029-08-19 | DP | U-2167 | 
| 10441194 | 2029-07-26 | DP | |
| 8956288 | 2029-07-06 | DP | U-2167 | 
| 8674825 | 2029-04-09 | DP | U-2170 | 
| 9060708 | 2029-03-05 | DP | |
| 9258035 | 2029-03-05 | DP | |
| 9119554 | 2028-12-16 | DP | |
| 9444503 | 2027-11-19 | DP | U-2169 | 
| 7978064 | 2026-09-14 | DP | |
| 11476952 | 2026-04-28 | DP | |
| Aripiprazole, Abilify Asimtufii, Otsuka | |||
| 10517951 | 2033-04-23 | DP | U-814, U-3245 | 
| 11097007 | 2033-04-23 | DP | U-814, U-3245 | 
| 11638757 | 2033-04-23 | DP | U-814, U-3245 | 
| 8399469 | 2025-06-29 | DP | |
| 8338427 | 2025-03-15 | DP | U-543, U-1530, U-1633 | 
| 8338428 | 2023-08-06 | DP | U-543, U-1530, U-1633 | 
| 8759351 | 2023-08-06 | DP | U-1530, U-1633 | 
| Aripiprazole, Abilify, Otsuka | |||
| 8759350 | 2027-03-02 | U-1529 | |
| 9125939 | 2026-07-28 | U-1749 | |
| 7115587 | 2024-07-21 | DP | U-764 | 
| 7550445 | 2024-07-21 | DP | |
| 8017615 | 2024-06-16 | DP | |
| 9387182 | 2023-12-25 | U-1529 | |

| Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total | 
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | 10 | 8 | 31 | 13 | 7 | 66 | 
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 3 | 3 | 19 | 4 | 4 | 32 | 
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | 11 | 2 | 2 | 16 | 
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 1 | 11 | 2 | 2 | 16 | 
| Depression | D003863 | — | F33.9 | — | 1 | 11 | 2 | 1 | 15 | 
| Psychotic disorders | D011618 | — | F20.81 | — | — | 5 | 3 | 2 | 10 | 
| Mental disorders | D001523 | EFO_0000677 | F91.9 | 1 | 2 | 1 | 2 | 3 | 9 | 
| Tourette syndrome | D005879 | EFO_0004895 | F95.2 | — | — | 6 | 1 | — | 7 | 
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | 1 | 1 | — | 2 | 
| Physiological sexual dysfunction | D012735 | — | — | — | — | — | 1 | — | 1 | 
| Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total | 
|---|---|---|---|---|---|---|---|---|---|
| Autistic disorder | D001321 | EFO_0003758 | F84.0 | — | — | 5 | — | 1 | 6 | 
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | — | 5 | — | — | 5 | 
| Dementia | D003704 | EFO_0003862 | F03 | — | — | 3 | — | — | 3 | 
| Tic disorders | D013981 | — | F95 | — | — | 3 | — | — | 3 | 
| Tics | D020323 | — | — | — | — | 3 | — | — | 3 | 
| Mania | D000087122 | — | F30 | — | 1 | 1 | — | — | 2 | 
| Behavioral symptoms | D001526 | — | — | — | — | 2 | — | — | 2 | 
| Psychomotor agitation | D011595 | — | — | — | — | 1 | — | — | 1 | 
| Problem behavior | D000066553 | — | — | — | — | 1 | — | — | 1 | 
| Schizophrenia spectrum and other psychotic disorders | D019967 | — | — | — | — | 1 | — | — | 1 | 
| Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total | 
|---|---|---|---|---|---|---|---|---|---|
| Nervous system diseases | D009422 | — | G00-G99 | 1 | 2 | — | — | 1 | 4 | 
| Hyperkinesis | D006948 | — | — | — | 1 | — | — | — | 1 | 
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | 1 | — | — | — | 1 | 
| Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total | 
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 | 
| Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total | 
|---|---|---|---|---|---|---|---|---|---|
| Psychotic affective disorders | D000341 | — | F39 | — | — | — | — | 1 | 1 | 
| Mood disorders | D019964 | EFO_0004247 | F30-F39 | — | — | — | — | 1 | 1 | 
| Drug common name | Aripiprazole | 
| INN | aripiprazole | 
| Description | Aripiprazole is an N-arylpiperazine that is piperazine substituted by a 4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl group at position 1 and by a 2,3-dichlorophenyl group at position 4. It is an antipsychotic drug used for the treatment of Schizophrenia, and other mood disorders. It has a role as a H1-receptor antagonist, a serotonergic agonist, a second generation antipsychotic and a drug metabolite. It is a quinolone, a N-arylpiperazine, a N-alkylpiperazine, a dichlorobenzene, an aromatic ether and a delta-lactam. | 
| Classification | Small molecule | 
| Drug class | antiulcer agents (benzimidazole derivatives) | 
| Image (chem structure or protein) |  | 
| Structure (InChI/SMILES or Protein Sequence) | O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1 | 
| PDB | — | 
| CAS-ID | 129722-12-9 | 
| RxCUI | — | 
| ChEMBL ID | CHEMBL1112 | 
| ChEBI ID | 31236 | 
| PubChem CID | 60795 | 
| DrugBank | DB01238 | 
| UNII ID | 82VFR53I78 (ChemIDplus, GSRS) | 










